Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Avalon GloboCare ( (ALBT) ) is now available.
On January 12, 2026, Avalon GloboCare announced that it had received confirmation from Nasdaq that the company regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement under Listing Rule 5550(b), restoring its full compliance with all continued listing standards. As a result, a previously scheduled hearing before the Nasdaq Hearings Panel was cancelled and Avalon’s common stock will continue to trade on the Nasdaq Capital Market, a development the company’s leadership framed as evidence of a strengthened financial position and a foundation for pursuing growth initiatives, including marketing its automated generative AI video platform and expanding its precision diagnostics and strategic assets portfolio.
More about Avalon GloboCare
Avalon GloboCare Corp. (NASDAQ: ALBT) is a diversified company focused on precision diagnostic consumer products and the advancement of intellectual property in cellular therapy and generative artificial intelligence publishing and software through its Avalon Quantum AI, LLC subsidiary. The company is currently marketing the FDA-registered KetoAir™ breathalyzer device as a Class I medical device and plans to develop additional diagnostic applications for this breathalyzer technology, while also maintaining a portfolio of patent applications and owning and operating commercial real estate.
Average Trading Volume: 89,292
Technical Sentiment Signal: Sell
Current Market Cap: $5.7M
For a thorough assessment of ALBT stock, go to TipRanks’ Stock Analysis page.